Literature DB >> 15029982

Target blood pressure for patients with type 2 diabetes is difficult to achieve in the setting of a busy diabetes clinic.

A Agha1, D Dillon, M Corbett, S Sreenan.   

Abstract

BACKGROUND: Target blood pressure control in patients with type 2 diabetes should be 130/85 mmHg or less; however, it is not clear how achievable this target is in clinical practice. AIM: To assess the adequacy of blood pressure control in patients with type 2 diabetes attending a busy outpatient clinic.
METHODS: One hundred and eight patients with type 2 diabetes were assessed for the presence of hypertension using a cut-off value of 130/85 mmHg. Antihypertensive treatment and diabetic complications were evaluated.
RESULTS: Hypertension was present in 67% of patients, in whom 90% were receiving anti-hypertensive treatment. Forty-nine per cent of the treated patients achieved target blood pressure. Of the undertreated patients, 55% were on one antihypertensive agent, 30% were on two agents and 15% were on three or more agents. The corresponding figures for the adequately treated patients were 28%, 31% and 41%, respectively (p=0.03).
CONCLUSION: Adequate blood pressure control was underachieved in this patient group underlying the difficulty in treating blood pressure to target values in patients with type 2 diabetes in the setting of outpatient diabetes clinics. A more aggressive strategy, in particular the use of multiple antihypertensive agents should be adopted.

Entities:  

Mesh:

Year:  2003        PMID: 15029982     DOI: 10.1007/BF02915282

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group.

Authors:  J M Lazarus; J J Bourgoignie; V M Buckalew; T Greene; A S Levey; N C Milas; L Paranandi; J C Peterson; J G Porush; S Rauch; J M Soucie; C Stollar
Journal:  Hypertension       Date:  1997-02       Impact factor: 10.190

2.  White-coat hypertension: misnomers, misconceptions and misunderstandings. What should we do next?

Authors:  G Mancia; A Zanchetti
Journal:  J Hypertens       Date:  1996-09       Impact factor: 4.844

3.  Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines?

Authors:  P B George; K J Tobin; R A Corpus; W H Devlin; W W O'Neill
Journal:  Am Heart J       Date:  2001-11       Impact factor: 4.749

4.  Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.

Authors:  J Tuomilehto; D Rastenyte; W H Birkenhäger; L Thijs; R Antikainen; C J Bulpitt; A E Fletcher; F Forette; A Goldhaber; P Palatini; C Sarti; R Fagard
Journal:  N Engl J Med       Date:  1999-03-04       Impact factor: 91.245

5.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.

Authors: 
Journal:  BMJ       Date:  1998-09-12

6.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

Review 7.  Hypertension and diabetes: new therapeutic options.

Authors:  P C Deedwania
Journal:  Arch Intern Med       Date:  2000-06-12

Review 8.  Guidelines for management of hypertension: report of the third working party of the British Hypertension Society.

Authors:  L Ramsay; B Williams; G Johnston; G MacGregor; L Poston; J Potter; N Poulter; G Russell
Journal:  J Hum Hypertens       Date:  1999-09       Impact factor: 3.012

9.  Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study.

Authors:  W B Kannel; D L McGee
Journal:  Diabetes Care       Date:  1979 Mar-Apr       Impact factor: 19.112

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

View more
  3 in total

1.  Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes.

Authors:  M Sherlock; D Mylotte; J Mac Mahon; K B Moore; C J Thompson
Journal:  Ir J Med Sci       Date:  2006 Oct-Dec       Impact factor: 1.568

2.  Quality of cardiovascular disease care in Ontario, Canada: missed opportunities for prevention - a cross sectional study.

Authors:  Clare Liddy; Jatinderpreet Singh; William Hogg; Simone Dahrouge; Catherine Deri-Armstrong; Grant Russell; Monica Taljaard; Ayub Akbari; George Wells
Journal:  BMC Cardiovasc Disord       Date:  2012-09-12       Impact factor: 2.298

Review 3.  Prevalence of hypertension and obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review.

Authors:  Ann D Colosia; Roberto Palencia; Shahnaz Khan
Journal:  Diabetes Metab Syndr Obes       Date:  2013-09-17       Impact factor: 3.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.